公开(公告)号：EP4332242A1

公开(公告)日：2024-03-06

申请号：EP22796218.0

申请日：2022-04-29

申请人： Industry-Academic Cooperation Foundation, Yonsei University

发明人： CHEONG, Jae-Ho ,  KIM, Jae-woo ,  YOON, Bo Kyung

IPC分类号： C12Q1/6886 ,  G01N33/574

摘要： A composition and method according to the present invention may be very effectively used to diagnose malignant gastric cancer and predict the prognosis of gastric cancer.

公开(公告)号：EP4364740A1

公开(公告)日：2024-05-08

申请号：EP22833558.4

申请日：2022-06-28

申请人： Industry-Academic Cooperation Foundation Yonsei University ,  Veraverse

发明人： CHEONG, Jae-Ho ,  KIM, Jae-woo ,  FANG, Sungsoon ,  YOON, Bo Kyung ,  KIM, Hyeonhui

IPC分类号： A61K31/501 ,  A61K31/496 ,  A61K31/4162 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  A61P35/00 ,  G01N33/68 ,  C12Q1/6883

CPC分类号： A61K31/501 ,  A61K31/713 ,  A61K31/7105 ,  A61P35/00 ,  A61K45/06 ,  A61K31/4162 ,  A61K31/496 ,  C12Q1/6883 ,  G01N33/68

摘要： The present invention relates to a method for prevention, alleviation, or treatment of cancer patients, especially epithelial mesenchymal transition (EMP)-subtype cancer patients. If PHGDH, SHMT and MTHFD2 inhibitors are co-administered to patients with cancer in which the expression level of a glutaminase (GLS) gene or a protein encoded thereby has increased, 1C metabolism is more effectively inhibited such that there is a synergistic effect on the inhibition of cancer cell proliferation in patients with refractory cancer that is difficult to treat because of recurrence, metastasis, and anticancer drug resistance, thereby enabling cancer to be very effectively treated. In addition, the expression level of the GLS gene or protein encoded thereby is measured so that information related to customized treatment methods from initial stages is provided to each patient and the success of treatment can be increased.

公开(公告)号：EP4295848A1

公开(公告)日：2023-12-27

申请号：EP22756488.7

申请日：2022-02-16

申请人： Industry-Academic Cooperation Foundation, Yonsei University

发明人： CHEONG, Jae-Ho ,  KIM, Jae-woo ,  YOON, Bo Kyung

IPC分类号： A61K31/4545 ,  A61K31/4525 ,  A61K33/243 ,  A61K45/06 ,  A61P35/00

摘要： A composition according to the present invention, when used alone, is capable of inhibiting the growth of anticancer drug-resistant cancer by overcoming anticancer drug resistance or enhancing anticancer drug sensitivity, and when co-administered with an anticancer drug, may be used very effectively for the prevention, alleviation or treatment of various cancers, especially anticancer drug-resistant cancer.